trial

Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

NCTId NCT03983018
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 9 (actual)
Sponsored by Region Örebro County
Primary completion 2022-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
9 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-08-07
Primary completion
2022-03-31
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Rituximab

Sponsors

Region Örebro CountyLead Sponsor
Örebro University, SwedenCollaborator

Investigators

1
Susanne Bejerot, MD, PhDPrincipal Investigator

Sites

1 total
Örebro, Sweden

Linked catalysts

1
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) — primary completion2022-03-31

Facts & assertions

4 sourced
Enrollment
9
Phase
PHASE2
Primary Completion Date
2022-03-31
Status
COMPLETED
relationships
The graph out of here
drug
Rituximab
drug
lead_sponsor
Region Örebro County
company
collaborator
Örebro University, Sweden
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia, Treatment-Resistant
indication
investigator
Susanne Bejerot, MD, PhD
person